Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Lymphoma Myeloma. 2006 Sep;7(2):125-30.

Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab.

Author information

  • 1Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston , TX 77030, USA. sobrien@mdanderson.org

Abstract

The anti-CD52 monoclonal antibody alemtuzumab is highly active in the treatment of chronic lymphocytic leukemia (CLL) in patients with previously treated, relapsed, and/or refractory CLL as well as in patients with previously untreated disease. The general immunosuppressive impact and toxicities associated with alemtuzumab therapy are largely predictable and manageable. In particular, cytomegalovirus (CMV) reactivation is now a well-documented complication in patients receiving alemtuzumab. This article discusses several strategies for monitoring and treating CMV reactivation in patients with CLL receiving alemtuzumab-based therapy and provides practical recommendations for CMV management by building upon the guidelines published previously in 2004.

PMID:
17026823
DOI:
10.3816/CLM.2006.n.049
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center